These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND CgA AND Staging
25 results:

  • 1. Larger tumor Size and Elevated Serum Chromogranin A Levels Predict Metastatic Disease on DOTATATE Imaging in Patients with Gastroenteropancreatic Neuroendocrine tumors.
    Labora A; Shimizu T; Moore A; Premji A; Armstrong WR; Chen KY; Link J; Chan CS; Allen-Auerbach MS; Donahue TR
    Ann Surg Oncol; 2024 Oct; 31(10):6875-6882. PubMed ID: 38909116
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].
    Zhang BL; Lu YX; Liang WQ; Gao YH; Xi HQ; Wang XX; Zhang KC; Chen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):459-466. PubMed ID: 37217354
    [No Abstract]    [Full Text] [Related]  

  • 3. Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine tumors: A Brief Report.
    Nisman B; Oleinikov K; Nechushtan H; Maimon O; Atlan K; Peled N; Gross D; Peretz T; Meirovitz A; Grozinsky-Glasberg S
    J Thorac Oncol; 2023 Mar; 18(3):369-376. PubMed ID: 36503175
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Prognostic significance of the aberrant expression of neuroendocrine markers in melanomas.
    Wu Y; Lai Y; Zhang M; Li Z
    Diagn Pathol; 2021 Aug; 16(1):78. PubMed ID: 34454530
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Risk factors for progression of appendiceal neuroendocrine tumours: low-stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation.
    Noor M; Huber AR; Cates JMM; Gonzalez RS
    Histopathology; 2021 Sep; 79(3):416-426. PubMed ID: 33754384
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine tumors: An ENETS Center of Excellence Experience.
    Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
    Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Volumetric 68Ga-DOTA-TATE PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
    Ohlendorf F; Henkenberens C; Brunkhorst T; Ross TL; Christiansen H; Bengel FM; Derlin T
    Q J Nucl Med Mol Imaging; 2022 Dec; 66(4):361-371. PubMed ID: 32286768
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes.
    Cheng Y; Zhan H; Wang L; Xu J; Zhang G; Zhang Z; Hu S
    Front Med; 2016 Dec; 10(4):444-450. PubMed ID: 27757796
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.
    Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW
    Eur J Endocrinol; 2016 Nov; 175(5):361-6. PubMed ID: 27491374
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D; Mikołajczak R; Kamiński G
    Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
    Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases.
    Ye L; Ye H; Zhou Q; Li Z; Lin Q; Tan L; Gao W; Fu Z; Zheng S; Chen R
    Int J Surg; 2016 May; 29():108-17. PubMed ID: 27000717
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Surgical Management of Small Bowel Neuroendocrine tumors: Specific Requirements and Their Impact on staging and Prognosis.
    Pasquer A; Walter T; Hervieu V; Forestier J; Scoazec JY; Lombard-Bohas C; Poncet G
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S742-9. PubMed ID: 26014153
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.
    Bodei L; Kidd M; Modlin IM; Prasad V; Severi S; Ambrosini V; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G; Drozdov I
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1341-52. PubMed ID: 25947577
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, germany.
    Hörsch D; Schmid KW; Anlauf M; Darwiche K; Denecke T; Baum RP; Spitzweg C; Grohé C; Presselt N; Stremmel C; Heigener DF; Serke M; Kegel T; Pavel M; Waller CF; Deppermann KM; Arnold R; Huber RM; Weber MM; Hoffmann H
    Oncol Res Treat; 2014; 37(5):266-76. PubMed ID: 24853787
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Evaluation of radiological prognostic factors of hepatic metastases in patients with non-functional pancreatic neuroendocrine tumors.
    Denecke T; Baur AD; Ihm C; Steffen IG; Tischer E; Arsenic R; Pascher A; Wiedenmann B; Pavel M
    Eur J Radiol; 2013 Oct; 82(10):e550-5. PubMed ID: 23891296
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Selected neuroendocrine tumour markers, growth factors and their receptors in typical and atypical bronchopulmonary carcinoids.
    Telega A; Kos-Kudła B; Foltyn W; Blicharz-Dorniak J; Rosiek V
    Endokrynol Pol; 2012; 63(6):477-82. PubMed ID: 23339006
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Comparison of PCR-based detection of chromogranin A mRNA with traditional histological lymph node staging of small intestinal neuroendocrine neoplasia.
    Lawrence B; Kenney B; Svejda B; Schimmack S; Alaimo D; Barbieri A; Jedrych J; Kidd M; Modlin I
    BMC Res Notes; 2012 Jun; 5():318. PubMed ID: 22720672
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Usefulness of chromogranin A, neuron-specific enolase and 5-hydroxyindolacetic acid measurements in patients with malignant carcinoids.
    Manfé AZ; Norberto L; Marchesini M; Lumachi F
    In Vivo; 2011; 25(6):1027-9. PubMed ID: 22021701
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors.
    Lindholm DP; Oberg K
    Horm Metab Res; 2011 Nov; 43(12):832-7. PubMed ID: 22009449
    [TBL] [Abstract] [Full Text] [Related]  

    [Next]

    of 2.